<?xml version="1.0" encoding="UTF-8"?>
<ref id="B13">
 <label>13</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Fukuoka</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Hara</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Takahashi</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Kojima</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Kawazoe</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Asayama</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)</article-title>. 
  <source>J Clin Oncol</source> (
  <year>2020</year>) 
  <volume>38</volume>:
  <page-range>2053–61</page-range>.  
  <pub-id pub-id-type="doi">10.1001/jamaoncol.2020.0910</pub-id>
 </mixed-citation>
</ref>
